Tonix Pharmaceuticals Holding Corp.(TNXP)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,618 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
TNXP Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Tonix Pharmaceuticals Holding Corp. (TNXP), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TNXP at 26.5/100 on a 32-signal composite quality model, placing it at rank #2,618 of 2,962 stocks — the bottom half of the AI-ranked universe. TNXP scores in the top quartile across institutional flow (95.6), revenue growth (91.6). Areas of concern include balance sheet strength (2.0) and free cash flow (2.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Tonix Pharmaceuticals Holding Corp. reports quarterly revenue of $13.5M, net income of $-40.6M, free cash flow of $-42.8M. Top institutional holders of TNXP by reported 13-F value include BlackRock, Point72 Asset Management, L.P., MILLENNIUM MANAGEMENT, based on the most recent SEC filings. TNXP trades on the Nasdaq exchange and files with the SEC under CIK 1430306. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TNXP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tonix Pharmaceuticals Holding Corp. directly from SEC EDGAR. Tonix Pharmaceuticals Holding Corp.'s 13F Pro composite quality score has ranged between 9 and 29 since 2025, currently 26.5 — an improving long-term trajectory across 51 quarterly and live scoring snapshots.
Revenue
Q2 2026
$13.5M
Net Income
Q2 2026
$-40.6M
Free Cash Flow
Q2 2026
$-42.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+29.8% YoYNet Income
+4.6% YoYOperating Income
+8.0% YoYEPS (Diluted)
+91.7% YoYTotal Assets
+70.2% YoYTotal Debt
Op. Cash Flow
-63.9% YoYFree Cash Flow
-69.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $13.1M +29.8% | $10.1M +29.9% | $7.8M | — | — | — |
| Net Income | $-124.0M +4.6% | $-130.0M -11.5% | $-116.7M -5.8% | $-110.2M -19.4% | $-92.3M -82.9% | $-50.5M |
| Operating Income | $-125.7M +8.0% | $-136.7M -15.5% | $-118.4M -5.6% | $-112.1M -21.4% | $-92.3M -82.8% | $-50.5M |
| EPS (Diluted) | $-14.57 +91.7% | $-176.60 +98.8% | $-14720.25 -73464.5% | $-20.01 -147.0% | $-8.10 | — |
| Total Assets | $277.2M +70.2% | $162.9M +5.5% | $154.5M -31.6% | $225.7M -6.3% | $240.9M +145.4% | $98.2M |
| Total Debt | — | $11.5M -14.1% | $13.3M | — | — | — |
| Operating Cash Flow | $-99.8M -63.9% | $-60.9M +40.3% | $-102.0M -4.0% | $-98.1M -29.8% | $-75.6M -55.6% | $-48.6M |
| Free Cash Flow | $-103.2M -69.1% | $-61.0M +44.5% | $-109.9M +24.8% | $-146.2M -31.9% | $-110.9M -94.1% | $-57.1M |
Get alerted when TNXP's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Tonix Pharmaceuticals Holding Corp. including:
Top Institutional Holders of TNXP
BlackRock, Inc.
$17.8M1,398,041 shPoint72 Asset Management, L.P.
$14.9M1,166,752 shMILLENNIUM MANAGEMENT LLC
$12.3M966,932 shAQR CAPITAL MANAGEMENT LLC
$11.3M882,595 shVANGUARD CAPITAL MANAGEMENT LLC
$8.8M691,895 shJones Hill Capital LP
$8.0M625,428 shGEODE CAPITAL MANAGEMENT, LLC
$5.0M395,260 shIshara Investments LP
$4.3M338,250 shSTATE STREET CORP
$3.5M271,374 shUBS Group AG
$3.0M231,682 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $17.8M | 1,398,041 |
| Point72 Asset Management, L.P. | $14.9M | 1,166,752 |
| MILLENNIUM MANAGEMENT LLC | $12.3M | 966,932 |
| AQR CAPITAL MANAGEMENT LLC | $11.3M | 882,595 |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.8M | 691,895 |
| Jones Hill Capital LP | $8.0M | 625,428 |
| GEODE CAPITAL MANAGEMENT, LLC | $5.0M | 395,260 |
| Ishara Investments LP | $4.3M | 338,250 |
| STATE STREET CORP | $3.5M | 271,374 |
| UBS Group AG | $3.0M | 231,682 |
Companies Similar to TNXP
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Vir Biotechnology, Inc.
Nuvation Bio Inc.
Axsome Therapeutics, Inc.
Editas Medicine, Inc.
Altimmune, Inc.
Inhibrx Biosciences, Inc.
Kura Oncology, Inc.
LEXICON PHARMACEUTICALS, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put TNXP on your watchlist
Track score changes the day Tonix Pharmaceuticals Holding Corp. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TNXP a good stock to buy?
13F Pro's AI-powered analysis of Tonix Pharmaceuticals Holding Corp. (TNXP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TNXP are available on the TNXP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TNXP is classified as a small company.
Which hedge funds own TNXP?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TNXP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Tonix Pharmaceuticals Holding Corp.'s investment landscape.